NEW YORK, NY--(Marketwire - October 06, 2008) - Delcath Systems, Inc. (NASDAQ: DCTH) reported that the Adjunct Principal Investigator for its Phase III clinical trial, James Pingpank, Jr., MD, discussed interim results from its randomized study of high-dose melphalan, delivered via the Company's Percutaneous Hepatic Perfusion (PHP) system, in patients with inoperable liver metastases from melanoma. Dr. Pingpank's presentation entitled "Targeted Chemotherapy: Minimally Invasive Percutaneous Hepatic Perfusion" was made on Saturday, October 4 at the "Perspectives in Melanoma XII" Meeting in The Hague, The Netherlands.
